Buy this domain?
Click Here

June 2019
M T W T F S S
     
 12
3456789
10111213141516
17181920212223
24252627282930

Search

ato.my
Alemtuzumab
Alemtuzumab is a drug used in the treatment of chronic lymphocytic leukemia (CLL), cutaneous T-cell lymphoma (CTCL) and T-cell lymphoma under the trade
CD52
associated with certain types of lymphoma. It is the protein targeted by alemtuzumab, a monoclonal antibody used for the treatment of chronic lymphocytic
Humanized antibody
synthesis of linear DNA fragments based on the reading of CDR sequences. Alemtuzumab is an early example of an antibody whose humanization did not include
Monoclonal antibody
Fc region. MAbs approved by the FDA (for cancer) as of 2005 include: Alemtuzumab Bevacizumab Cetuximab Gemtuzumab ozogamicin Ipilimumab Ofatumumab Panitumumab
Cancer immunotherapy
which can lead to cell death. Approved immunotherapy antibodies include alemtuzumab, ipilimumab, nivolumab, ofatumumab, pembrolizumab and rituximab. Active
Management of multiple sclerosis
interferons beta-1a and beta-1b, three monoclonal antibodies: natalizumab, alemtuzumab, ocrelizumab, and five immunomodulators: glatiramer acetate, mitoxantrone
Cladribine
be a highly effective immune reconstitution therapy in MS. Similar to alemtuzumab, cladribine is given as two courses approximately one year apart. Each
Chronic lymphocytic leukemia
antibodies against CD20 (rituximab, ofatumumab and obinutuzumab) and CD52 (alemtuzumab). Autologous stem cell transplantation, using the recipient's own cells
Leukemia
doxorubicin, prednisone, etoposide, cyclophosphamide, bleomycin VAPEC-B). Alemtuzumab (Campath), a monoclonal antibody that attacks white blood cells, has
Multiple sclerosis
mitoxantrone, natalizumab, fingolimod, teriflunomide, dimethyl fumarate, alemtuzumab, ocrelizumab, siponimod, and cladribine. Their cost effectiveness as